Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Response to "Standardized methods must be used to compare the properties of botulinum toxin serotypes".

Kohda T, Nakamura K, Hosomi K, Torii Y, Kozaki S, Mukamoto M.

Microbiol Immunol. 2017 Dec;61(12):560. doi: 10.1111/1348-0421.12552. No abstract available.

PMID:
29115685
2.

A case of dedifferentiated liposarcoma of the heart and stomach.

Hisata Y, Tasaki Y, Kozaki S, Yamada T.

Int J Surg Case Rep. 2017;41:36-38. doi: 10.1016/j.ijscr.2017.10.001. Epub 2017 Oct 6.

3.

Characterization of the functional activity of botulinum neurotoxin subtype B6.

Kohda T, Nakamura K, Hosomi K, Torii Y, Kozaki S, Mukamoto M.

Microbiol Immunol. 2017 Nov;61(11):482-489. doi: 10.1111/1348-0421.12540.

PMID:
28898517
4.

Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan.

Torii Y, Sugimoto N, Kohda T, Kozaki S, Morokuma K, Horikawa Y, Ginnaga A, Yamamoto A, Takahashi M.

Jpn J Infect Dis. 2017 Jul 24;70(4):423-429. doi: 10.7883/yoken.JJID.2016.360. Epub 2017 Feb 28.

5.

Screening of mammalian DNA polymerase and topoisomerase inhibitors from Garcinia mangostana L. and analysis of human cancer cell proliferation and apoptosis.

Onodera T, Takenaka Y, Kozaki S, Tanahashi T, Mizushina Y.

Int J Oncol. 2016 Mar;48(3):1145-54. doi: 10.3892/ijo.2016.3321. Epub 2016 Jan 5.

PMID:
26781450
6.

Retrospective survey to evaluate the safety and efficacy of Japanese botulinum antitoxin therapy in Japan.

Mottate K, Yokote H, Mori S, Horita A, Miyatsu Y, Torii Y, Kozaki S, Iwaki M, Takahashi M, Ginnaga A.

Toxicon. 2016 Feb;110:12-8. doi: 10.1016/j.toxicon.2015.11.010. Epub 2015 Nov 22.

PMID:
26615088
7.

Genotyping and characterisation of the secretory lipolytic enzymes of Malassezia pachydermatis isolates collected from dogs.

Teramoto H, Kumeda Y, Yokoigawa K, Hosomi K, Kozaki S, Mukamoto M, Kohda T.

Vet Rec Open. 2015 Aug 21;2(2):e000124. doi: 10.1136/vetreco-2015-000124. eCollection 2015.

8.

Morphological and genetic characterization of group I Clostridium botulinum type B strain 111 and the transcriptional regulator spoIIID gene knockout mutant in sporulation.

Hosomi K, Kuwana R, Takamatsu H, Kohda T, Kozaki S, Mukamoto M.

Anaerobe. 2015 Jun;33:55-63. doi: 10.1016/j.anaerobe.2015.01.012. Epub 2015 Jan 31.

PMID:
25652599
9.

Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats.

Torii Y, Goto Y, Nakahira S, Kozaki S, Kaji R, Ginnaga A.

Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):524-8. doi: 10.1111/bcpt.12351. Epub 2014 Dec 17.

10.

Complete nucleotide sequence of a plasmid containing the botulinum neurotoxin gene in Clostridium botulinum type B strain 111 isolated from an infant patient in Japan.

Hosomi K, Sakaguchi Y, Kohda T, Gotoh K, Motooka D, Nakamura S, Umeda K, Iida T, Kozaki S, Mukamoto M.

Mol Genet Genomics. 2014 Dec;289(6):1267-74. doi: 10.1007/s00438-014-0887-4. Epub 2014 Aug 23.

PMID:
25149145
11.

Difficult preoperative diagnosis in a case of rapidly progressive carcinomatous pericarditis.

Wada T, Anai H, Shuto T, Okamoto K, Kawano M, Kozaki S, Hirota J, Miyamoto S.

Gen Thorac Cardiovasc Surg. 2016 Apr;64(4):227-30. doi: 10.1007/s11748-014-0440-8. Epub 2014 Jul 1.

PMID:
24980145
12.

Botulinum neurotoxin type A subtype 2 confers greater safety than subtype 1 in a rat Parkinson's disease model.

Itakura M, Kohda T, Kubo T, Semi Y, Nishiyama K, Azuma YT, Nakajima H, Kozaki S, Takeuchi T.

J Vet Med Sci. 2014 Aug;76(8):1189-93. Epub 2014 May 21.

13.

Botulinum neurotoxin A subtype 2 reduces pathological behaviors more effectively than subtype 1 in a rat Parkinson's disease model.

Itakura M, Kohda T, Kubo T, Semi Y, Azuma YT, Nakajima H, Kozaki S, Takeuchi T.

Biochem Biophys Res Commun. 2014 May 2;447(2):311-4. doi: 10.1016/j.bbrc.2014.03.146. Epub 2014 Apr 5.

PMID:
24713302
14.

Comparison between botulinum neurotoxin type A2 and type A1 by electrophysiological study in healthy individuals.

Mukai Y, Shimatani Y, Sako W, Asanuma K, Nodera H, Sakamoto T, Izumi Y, Kohda T, Kozaki S, Kaji R.

Toxicon. 2014 Apr;81:32-6. doi: 10.1016/j.toxicon.2013.12.012. Epub 2014 Feb 1.

PMID:
24495439
15.

Molecular characterization of Clostridium botulinum isolates from foodborne outbreaks in Thailand, 2010.

Wangroongsarb P, Kohda T, Jittaprasartsin C, Suthivarakom K, Kamthalang T, Umeda K, Sawanpanyalert P, Kozaki S, Ikuta K.

PLoS One. 2014 Jan 27;9(1):e77792. doi: 10.1371/journal.pone.0077792. eCollection 2014.

16.

Draft Genome Sequence of Clostridium botulinum Type B Strain Osaka05, Isolated from an Infant Patient with Botulism in Japan.

Sakaguchi Y, Hosomi K, Uchiyama J, Ogura Y, Umeda K, Sakaguchi M, Kohda T, Mukamoto M, Misawa N, Matsuzaki S, Hayashi T, Kozaki S.

Genome Announc. 2014 Jan 23;2(1). pii: e01010-13. doi: 10.1128/genomeA.01010-13.

17.

Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies.

Torii Y, Goto Y, Nakahira S, Kozaki S, Ginnaga A.

Toxicon. 2014 Jan;77:114-20. doi: 10.1016/j.toxicon.2013.11.006. Epub 2013 Nov 20.

PMID:
24269688
18.

Three acetophenones from Acronychia pedunculata.

Kozaki S, Takenaka Y, Mizushina Y, Yamaura T, Tanahashi T.

J Nat Med. 2014 Apr;68(2):421-6. doi: 10.1007/s11418-013-0803-y. Epub 2013 Oct 16.

PMID:
24129772
19.

Botulinum neurotoxin A2 reduces incidence of seizures in mouse models of temporal lobe epilepsy.

Kato K, Akaike N, Kohda T, Torii Y, Goto Y, Harakawa T, Ginnaga A, Kaji R, Kozaki S.

Toxicon. 2013 Nov;74:109-15. doi: 10.1016/j.toxicon.2013.07.027. Epub 2013 Aug 15.

PMID:
23954512
20.

Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin.

Torii Y, Shinmura M, Kohda T, Kozaki S, Takahashi M, Ginnaga A.

Toxicon. 2013 Oct;73:9-16. doi: 10.1016/j.toxicon.2013.06.020. Epub 2013 Jul 5.

PMID:
23834917
21.

Multi-locus variable number tandem repeat analysis for Clostridium botulinum type B isolates in Japan: comparison with other isolates and genotyping methods.

Umeda K, Wada T, Kohda T, Kozaki S.

Infect Genet Evol. 2013 Jun;16:298-304. doi: 10.1016/j.meegid.2013.02.022. Epub 2013 Mar 14.

PMID:
23499776
22.

Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E.

Mukamoto M, Maeda H, Kohda T, Nozaki C, Takahashi M, Kozaki S.

Jpn J Infect Dis. 2013;66(1):46-50.

23.

Analysis of tryptophan-rich region in Clostridium septicum alpha-toxin involved with binding to glycosylphosphatidylinositol-anchored proteins.

Mukamoto M, Kimura R, Hang'ombe MB, Kohda T, Kozaki S.

Microbiol Immunol. 2013 Mar;57(3):163-9. doi: 10.1111/1348-0421.12017.

24.

Improved detection methods by genetic and immunological techniques for botulinum C/D and D/C mosaic neurotoxins.

Nakamura K, Kohda T, Seto Y, Mukamoto M, Kozaki S.

Vet Microbiol. 2013 Mar 23;162(2-4):881-90. doi: 10.1016/j.vetmic.2012.11.009. Epub 2012 Nov 10.

PMID:
23206412
25.

Transsynaptic inhibition of spinal transmission by A2 botulinum toxin.

Akaike N, Shin MC, Wakita M, Torii Y, Harakawa T, Ginnaga A, Kato K, Kaji R, Kozaki S.

J Physiol. 2013 Feb 15;591(4):1031-43. doi: 10.1113/jphysiol.2012.242131. Epub 2012 Oct 29.

26.

Inhibition of nitric oxide production and inducible nitric oxide synthase expression by a polymethoxyflavone from young fruits of Citrus unshiu in rat primary astrocytes.

Ihara H, Yamamoto H, Ida T, Tsutsuki H, Sakamoto T, Fujita T, Okada T, Kozaki S.

Biosci Biotechnol Biochem. 2012;76(10):1843-8. Epub 2012 Oct 7.

27.

Characterization of neutralizing mouse-human chimeric and shuffling antibodies against botulinum neurotoxin A.

Mukamoto M, Maeda H, Kohda T, Nozaki C, Takahashi M, Kozaki S.

Microbiol Immunol. 2012 Nov;56(11):748-55. doi: 10.1111/j.1348-0421.2012.00503.x.

28.

P19 embryonal carcinoma cells exhibit high sensitivity to botulinum type C and D/C mosaic neurotoxins.

Tsukamoto K, Arimitsu H, Ochi S, Nakamura K, Tanaka Y, Nuemket N, Taniguchi K, Kozaki S, Tsuji T.

Microbiol Immunol. 2012 Oct;56(10):664-72. doi: 10.1111/j.1348-0421.2012.00490.x.

29.

Unique biological activity of botulinum D/C mosaic neurotoxin in murine species.

Nakamura K, Kohda T, Shibata Y, Tsukamoto K, Arimitsu H, Hayashi M, Mukamoto M, Sasakawa N, Kozaki S.

Infect Immun. 2012 Aug;80(8):2886-93. doi: 10.1128/IAI.00302-12. Epub 2012 Jun 4.

30.

RNAi suppression of rice endogenous storage proteins enhances the production of rice-based Botulinum neutrotoxin type A vaccine.

Yuki Y, Mejima M, Kurokawa S, Hiroiwa T, Kong IG, Kuroda M, Takahashi Y, Nochi T, Tokuhara D, Kohda T, Kozaki S, Kiyono H.

Vaccine. 2012 Jun 13;30(28):4160-6. doi: 10.1016/j.vaccine.2012.04.064. Epub 2012 May 1.

PMID:
22554467
31.

Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.

Zhao H, Nakamura K, Kohda T, Mukamoto M, Kozaki S.

Jpn J Infect Dis. 2012;65(2):138-45.

32.

Stability of toxigenicity in proteolytic Clostridium botulinum type B upon serial passage.

Umeda K, Seto Y, Kohda T, Mukamoto M, Kozaki S.

Microbiol Immunol. 2012 May;56(5):338-41. doi: 10.1111/j.1348-0421.2012.00441.x.

33.

Specificity of botulinum protease for human VAMP family proteins.

Yamamoto H, Ida T, Tsutsuki H, Mori M, Matsumoto T, Kohda T, Mukamoto M, Goshima N, Kozaki S, Ihara H.

Microbiol Immunol. 2012 Apr;56(4):245-53. doi: 10.1111/j.1348-0421.2012.00434.x.

34.

Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons.

Shin MC, Wakita M, Xie DJ, Yamaga T, Iwata S, Torii Y, Harakawa T, Ginnaga A, Kozaki S, Akaike N.

J Pharmacol Sci. 2012;118(1):33-42. Epub 2011 Dec 10.

35.

Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats.

Torii Y, Akaike N, Harakawa T, Kato K, Sugimoto N, Goto Y, Nakahira S, Kohda T, Kozaki S, Kaji R, Ginnaga A.

J Pharmacol Sci. 2011;117(4):275-85. Epub 2011 Nov 26.

36.

Structural and mutational analyses of the receptor binding domain of botulinum D/C mosaic neurotoxin: insight into the ganglioside binding mechanism.

Nuemket N, Tanaka Y, Tsukamoto K, Tsuji T, Nakamura K, Kozaki S, Yao M, Tanaka I.

Biochem Biophys Res Commun. 2011 Jul 29;411(2):433-9. doi: 10.1016/j.bbrc.2011.06.173. Epub 2011 Jul 2.

PMID:
21749855
37.

Syntaxin 1B suppresses macropinocytosis and semaphorin 3A-induced growth cone collapse.

Kabayama H, Takeuchi M, Taniguchi M, Tokushige N, Kozaki S, Mizutani A, Nakamura T, Mikoshiba K.

J Neurosci. 2011 May 18;31(20):7357-64. doi: 10.1523/JNEUROSCI.2718-10.2011.

38.

Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test.

Torii Y, Kiyota N, Sugimoto N, Mori Y, Goto Y, Harakawa T, Nakahira S, Kaji R, Kozaki S, Ginnaga A.

Toxicon. 2011 Jan;57(1):93-9. doi: 10.1016/j.toxicon.2010.10.009. Epub 2010 Oct 26.

PMID:
21029745
39.

In vivo molecular imaging analysis of a nasal vaccine that induces protective immunity against botulism in nonhuman primates.

Yuki Y, Nochi T, Harada N, Katakai Y, Shibata H, Mejima M, Kohda T, Tokuhara D, Kurokawa S, Takahashi Y, Ono F, Kozaki S, Terao K, Tsukada H, Kiyono H.

J Immunol. 2010 Nov 1;185(9):5436-43. doi: 10.4049/jimmunol.1001789. Epub 2010 Sep 29.

40.

Two Japanese Corynebacterium ulcerans isolates from the same hospital: ribotype, toxigenicity and serum antitoxin titre.

Komiya T, Seto Y, De Zoysa A, Iwaki M, Hatanaka A, Tsunoda A, Arakawa Y, Kozaki S, Takahashi M.

J Med Microbiol. 2010 Dec;59(Pt 12):1497-504. doi: 10.1099/jmm.0.022491-0. Epub 2010 Sep 2.

PMID:
20813850
41.

Effects of low protein intake on the development of the remaining kidney in subtotally nephrectomized immature rats: expression of inducible and endothelial NO synthase.

Mino M, Ihara H, Kozaki S, Kondo T, Takeshita A, Kusakabe KT, Okada T.

Med Mol Morphol. 2010 Jun;43(2):116-22. doi: 10.1007/s00795-009-0485-4. Epub 2010 Aug 4.

PMID:
20683700
42.

Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses.

Akaike N, Ito Y, Shin MC, Nonaka K, Torii Y, Harakawa T, Ginnaga A, Kozaki S, Kaji R.

Toxicon. 2010 Dec;56(8):1315-26. doi: 10.1016/j.toxicon.2010.07.015. Epub 2010 Jul 30.

PMID:
20674584
43.

Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines.

Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima M, Kohda T, Harada N, Kong IG, Sato A, Kataoka N, Tokuhara D, Kurokawa S, Takahashi Y, Tsukada H, Kozaki S, Akiyoshi K, Kiyono H.

Nat Mater. 2010 Jul;9(7):572-8. doi: 10.1038/nmat2784. Epub 2010 Jun 20. Erratum in: Nat Mater. 2010 Aug;9(8):685.

PMID:
20562880
44.

A novel multiplex PCR method for Clostridium botulinum neurotoxin type A gene cluster typing.

Umeda K, Seto Y, Kohda T, Mukamoto M, Kozaki S.

Microbiol Immunol. 2010 May;54(5):308-12. doi: 10.1111/j.1348-0421.2010.00213.x.

45.

Preliminary X-ray crystallographic study of the receptor-binding domain of the D/C mosaic neurotoxin from Clostridium botulinum.

Nuemket N, Tanaka Y, Tsukamoto K, Tsuji T, Nakamura K, Kozaki S, Yao M, Tanaka I.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010 May 1;66(Pt 5):608-10. doi: 10.1107/S1744309110012182. Epub 2010 Apr 30.

46.

Change of thermal inactivation of Clostridium botulinum spores during rice cooking.

Konagaya Y, Urakami H, Hoshino J, Kobayashi A, Sasagawa A, Yamazaki A, Kozaki S, Tanaka N.

J Food Prot. 2009 Nov;72(11):2400-6.

PMID:
19903408
47.

Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP).

Torii Y, Takahashi M, Ishida S, Goto Y, Nakahira S, Harakawa T, Kaji R, Kozaki S, Ginnaga A.

Toxicon. 2010 Feb-Mar;55(2-3):662-5. doi: 10.1016/j.toxicon.2009.09.004. Epub 2009 Sep 22.

PMID:
19781565
48.

Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins.

Torii Y, Goto Y, Takahashi M, Ishida S, Harakawa T, Sakamoto T, Kaji R, Kozaki S, Ginnaga A.

Toxicon. 2010 Feb-Mar;55(2-3):407-14. doi: 10.1016/j.toxicon.2009.09.005. Epub 2009 Sep 22.

PMID:
19778548
49.

Characterization of the D/C mosaic neurotoxin produced by Clostridium botulinum associated with bovine botulism in Japan.

Nakamura K, Kohda T, Umeda K, Yamamoto H, Mukamoto M, Kozaki S.

Vet Microbiol. 2010 Jan 6;140(1-2):147-54. doi: 10.1016/j.vetmic.2009.07.023. Epub 2009 Aug 8.

PMID:
19720474
50.

[Application of botulinum neurotoxin in the treatment of epilepsy].

Kato K, Kohda T, Kozaki S.

Brain Nerve. 2009 Aug;61(8):939-48. Review. Japanese.

PMID:
19697883

Supplemental Content

Loading ...
Support Center